Celldex Therapeutics, Inc.
NASDAQCelldex Therapeutics enters the post-earnings stretch with a striking split: short sellers are unwinding at pace while the analyst community shifts decisively more constructive, yet the stock is still down 5.5% on the week. The short-interest unwind is the week's defining move. SI % FF has fallen from above 12.5% in mid-April to 10.2% now — a drop of more than two percentage points…
Snapshot as of 13 May 2026
Celldex Therapeutics enters the post-earnings stretch with a striking split: short sellers are unwinding at pace while the analyst community shifts decisively more constructive, yet the stock is still down 5.5% on the…
Celldex Therapeutics reports Q1 2026 results on May 11 with short sellers maintaining a meaningful position — but the borrow market tells a story of fading conviction rather than escalating pressure. Short interest is…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CLDX — free to start on ORTEX.
Sign up for free →Open CLDX on ORTEX